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Background: Newborn screening (NBS) for cystic ﬁbrosis (CF) can lead to the detection of healthy carriers. We report a unique assessment of
family testing following the identiﬁcation of carriers by NBS for over 20 years, in an area where CF is frequent.
Methods: We reviewed all of the carriers identiﬁed by NBS between 1991 and 2010 and registered the tests done in those families.
Results: NBS identiﬁed 0.1% of the newborns as carriers, which correspond only to 2.6% of the expected carriers born within the period, and 1/3 of
those with an increased IRT level. Of the 195 families, 75.9% requested testing (2.5 tests per family).
We identiﬁed 183 carriers and ﬁve 1-in-4 risk couples. Reassurance about genetic status was provided to 96% of the couples.
Conclusions: Carriers detected by NBS appeared to be well managed in our area, and cascade testing that informs on genetic status seems relatively
active.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Family testing; Carrier; Cystic ﬁbrosis; 1-in-4 risk couple; Newborn screening1. Introduction
Despite the absence of a cure, newborn screening (NBS) for
cystic fibrosis (CF) has been implemented in many areas,
allowing patients to receive early care withmeasurable nutritional
and respiratory benefits [1]. The introduction of DNA analysis
has greatly improved the test performances. However it has led
to the identification of some newborns carrying a single CF
mutation.⁎ Corresponding author at: Inserm U1078, 46 rue Félix Le Dantec, CS 51819,
29218 Brest Cedex 2, France. Tel.: +33 2 98 44 50 64; fax: +33 2 98 43 05 55.
E-mail address: ingrid.dugueperoux@univ-brest.fr (I. Duguépéroux).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.11.009Although being a carrier has no influence on the develop-
ment of the newborn, the knowledge of that status is
nonetheless important, as there may be reproductive implica-
tions. Indeed, in adulthood the carrier should be offered the
opportunity to discuss his/her status and the possible reproduc-
tive implications with a genetic counsellor. For parents, this
means that one of them is an obligate carrier and, therefore one
CFTR gene mutation segregates in the family. The parental
couple is, moreover, more likely to be a 1-in-4 risk couple (if
the partner is also a carrier) with the potential risk to give birth
to an affected child (a priori, this risk is approximately 1 in
100). Initially offered only to CF-affected family members,
family testing (also called cascade testing) has, since NBS was
implemented, been offered to families in whom a CF carrier
was identified. Parents and relatives can be informed of theirby Elsevier B.V. All rights reserved.
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future pregnancies [2].
Only few articles focused on cascade testing in families with CF
carriers children identified at birth [3–7]. Most of them reported
few requests for testing in extended family members. To our
knowledge, no similar measurements have been done in France.
Finistère (Brittany, Western France) was a pioneer district in
the implementation of NBS for CF. It was established in May
1988, and the procotol combining immunoreactive trypsin
(IRT) measure and DNA was introduced in January 1991
[8–12]. CF is particularly common in Brittany (incidence:
approximately 1 in 2500; carrier rate close to 1 in 25) and the
population, mostly of Celtic origin, is particularly aware of and
mobilised against the disease [13].
The present study aimed to assess the achievement of cascade
testing in parents and relatives of carrier children identified
through NBS and born over a 20-year period (1991–2010) in a
district of western France (Finistère), where CF is frequent and
that was a pioneer in the implementation of NBS.
2. Material and methods
2.1. Newborn screening
The aim of NBS for CF is the early detection of patients. Our
protocol, which consists of a three-step strategy, has been described
previously [10,14].
Children with one or two mutations are referred to the CF
centre, where a sweat test is performed. If the sweat test result is
below 30 mEq/l and only one mutation is present, the child is
considered as a carrier. If the sweat test result is between 30 and
60 mEq/l or slightly greater, further gene analyses are performed.Family member
Not carrying the  
familial mutation
STOP
Non carrier
Exons scanning 
Covering rate: 95%
Non carrier
STOP
Residual risk: 1/2500 Gene
1-in
Fig. 1. Flowchart of the cascade testinThe child is considered as a carrier if no additional mutation is
identified and no clinical sign evidenced. If an additional CF
causing mutation is identified, CF is diagnosed.
Parents are invited to meet a paediatrician, who explains the
test results in terms of child health and implications for the
family. They are also directed to a consultation at the Medical
Genetics Unit of the University Hospital.
2.2. Cascade testing
During this consultation, genetic aspects and possible risks
are discussed and cascade testing is first offered to the parents
of the carrier newborn. The aim of the genetic analysis is
threefold: to identify the parent sharing the mutation with the
child, to identify any couple who is at 1-in-4 risk and those low
risk couple. As no active cascade programme exists in France,
the genetic information is then disseminated by the parents to
family members. Individuals from the family branch in which
the mutation segregates who want to know their status
regarding CF have to contact the Medical Genetics Unit for
an appointment with the geneticist. Our strategy of testing for
relatives is summarised in Fig. 1.
2.3. Study population
We reviewed all carriers born in the district of Finistère (893
000 inhabitants; approximately 10 000 births per year) identified
by NBS since the introduction of the IRT/DNA protocol (period
1991–2010). The census was performed using data from the
Laboratory of Molecular Genetics of the University Hospital
(Brest). It is the sole genetic unit of our area and one of the
reference laboratories for CF in France. The validation wasCarrying the 
familial mutation
Study of the spouse
Commercial kit
Covering rate: 90%
Carrier
Carrier
tic counselling
-4 risk couple
1-in-4 risk couple
Genetic counselling
g strategy used in our laboratory.
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the data set from NBS in Brittany [15] and the Medical Genetics
Unit of the University Hospital (Brest), where prior genetic
counselling occurred.
2.4. Data collection
For each carrier newborn, we recorded the sex, month and
year of birth, mutation identified, date of molecular diagnostics,
IRT value (expressed in μg/l up to 2001 and in g/l thereafter) and
sweat test value (mEq/l), if available. For each relative who had
gene analysis, we recorded the year of birth, sex, month, year of
the test and result (negative or mutation(s) identified), whether
the subject was pregnant or considering pregnancy at the time of
the analysis and familial data (kinship and degree of relationship).
2.5. Statistical analysis
Data analysis was performed using EPI-INFO software (version
6.04) and SAS (version 9.2).
We first determined the number and percentage of carriers
identified by NBS. We described the characteristics of the carrier
children and the relatives who had testing. We calculated and
compared the mean duration from the time of the NBS result, the
proportion of tests performed according to kinship (e.g., parent,
sibling, uncle-aunt, cousin or grandparent), and the existence of a
current pregnancy or a parental project.
Focusing on impact on public health, we determined the
number of 1-in-4 risk couples identified through testing, the
number of consecutively performed prenatal diagnoses (PD), the
number of CF foetuses identified through PD, and the number of
resultant medical terminations of pregnancies.
Finally, we estimated the proportion of carriers identified by
our programme. Therefore, we compared the number of carriers
identified by NBS to that of expected carriers. We considered
the incidence of CF observed during the study period (q2) and
the carrier rate deduced (2pq) assuming the Hardy–Weinberg
equilibrium. Similar calculations were made based on the
population of infants who had a high IRT level at time of NBS.
3. Results
3.1. Description of the children identified as carriers by our
newborn screening programme
Among the 200 378 newborns screened in the district of
Finistère in the 1991–2010 period, 202 (0.1%) were identified
as CF carriers. Three of them were excluded from the study
because they were given up for adoption.
Of 199 healthy carriers included, 106 (53.3%) were females.
Twenty-one CFTR gene mutations were identified in that
population. The five most frequent alleles counted for 90.5% of
the total alleles detected. These were p.Phe508del [F508del]
(78.4%), p.Gly551Asp [G551D] (5.5%), p.Arg347His [R347H]
(3.0%), p.Phe316LeufsX12 [1078delT] (2.0%) and p.Gly542*
[G542X] (1.5%).Hypertrypsinemic carrier children (n=145) born from 1991 to
2001 (i.e., when the NBS existed only in our area) had mean IRT
and sweat test values equal to 980.9 μg/l−1 (range: 589.0–2
314.0) and 19.2 mEq/l (range: 7.0–64.0), respectively. Children
born after the NBS was generalised in 2002 (n=54) had mean
IRT and sweat test values equal to 80.5 g/l (range: 60.0–177.0)
and 15.2 mEq/l (range: 4.0–57.0) respectively.
The 199 carrier children belonged to 195 families; 47
families accounting for 48 children did not follow up with
family testing. In 38 (80.9%) of them, the carrier child (n=39)
was born before 2002. The biochemical values of the children
in this group did not differ significantly from the whole
population (IRT=932.6 μg/l−1; sweat test=11.3 mEq/l), and
over 75% carried the p.Phe508del allele.
Only nine families with carrier children born since 2002
declined family testing. The mean IRT value of that population
was 70.8 g/l−1 (median 66.0), and the sweat test was performed
for two of them (20.7 mEq/l). All shared CF causing mutations:
p.Phe508del (n=7) and p.Gly551Asp (n=2).
3.2. Description of carrier testing performed in those families
Testing in families who had at least one genetic test (n=148)
included a total of 374 tests (mean number per family: 2.5;
range: 1–8).
Parents appeared to be particularly interested in testing.
Indeed, 142 parental couples (95.9%) and 6 mothers alone were
tested.
In one case, genetic testing evidenced that neither of the
parents shared the mutation carried by the child (p.Phe508del).
Therefore kinship exclusion was hypothesized and the parental
couple was excluded from subsequent analyses.
Among the parents (141 couples and 6 mothers), the test was
generally conducted shortly after the evidence of the child status
(average time: 0.5 years (6 months); range: 0.1-7.1). Thirteen
parents (4.5%) had an on-going pregnancy or a parental project
at the time of testing. The average time at testing for this
specific group rose to 3.0 years (range: 0.7–7.0). In all cases,
the mutation carried by the child was identified in at least one
parent and 3 parental couples were 1-in-4 ones (Fig. 2).
Sixty-nine family members were tested and mutations were
found in 35 of them (41.7%). Of those found to be carriers 15
partners were also tested. Of those partners two were found to be
carriers leading to the identification of two 1-in-4 risk couples.
Thirty-eight uncles/aunts requested genetic testing (10.2% of
the tests performed). Mutations were identified in 23 of them
(60.5%). Thirteen partners of the carriers' uncles/aunts were also
tested, and two were determined to be carriers. All of the tested
couples and half of the uncles/aunts tested alone had an on-going
or wished to initiate a pregnancy. Uncles/aunts requested testing
at a mean of 3.4 years after NBS (range: 0.2–15.3), and when a
positive result was returned, the partner was tested within an
average of two months.
Fourteen siblings (3.8% of the tests performed) have been
tested, most of them during childhood at the parents' request,
during the early 1990s. Half of the tested siblings carried a
mutation. Two siblings' partners were tested later, and none
Tests performed (nr 374)
1-in-4 risk couple (nr 3)
Heterozygous children (nr 202)
Included (nr 199)
Families (nr 195)
Family Testing (nr 148)No Family Testing (nr 47)
Parents (nr 288)*
Including 141 couples
Siblings 
(nr 14)
Uncles/aunts
(nr 38)
Grands-parents 
(nr 6)
Cousins 
(nr 4)
Others relatives 
(nr 7)
Carriers
(nr 23; 60.5%)
Carriers
(nr 7; 50%)
Carriers 
(nr 3; 50%)
Carrier 
(nr 1; 25%)
Carrier 
(nr 1;14.3%)
Carriers
(nr 148; 51.3%)
Spouses (nr 13) Spouses
1-in-4 risk couple (nr 2)
PD (nr 4)
Affected pregnancy +  TOP 
(nr 1)
PD (nr 1)
Prior risk 50% Prior risk 25% Other prior risk
Carriers (nr 2; 15.4%)
(nr 2)
Fig. 2. Results of cascade testing performed in the carrier newborns' families (*1 parental couple was excluded because neither of the parents shared the mutation
carried by the screened child).
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pregnancy or parental project.
Six grandparents, including one couple, requested testing,
and three shared a deleterious allele. They asked for testing
within a year following NBS (mean time: 0.8 years, i.e.,
10 months; range: 0.3–2.5).
Four single cousins asked for family testing, including three
children of previously positively tested uncles/aunts, and one was
a carrier. Two were planning a pregnancy, and the genetic testing
occurred 9.2 years after NBS on average (range: 6.7–13.8).
Finally, seven other relatives were tested (e.g., first cousins
once removed), and only one was found to be a carrier. Two
reported pregnancy or parental project, and the test was
requested very shortly after the NBS result (1.6 year meanly;
range: 0.4–5.2).
Overall, cascade testing identified 183 CF carriers (i.e., 49.2%
of the tested individuals), and detected five new 1-in-4 risk
couples (three parental and two uncle/aunt couples). Four couples
requested a total of five PDs in subsequent pregnancies. Three
heterozygous pregnancies were detected and conduced to birth
and one affected was terminated. Over 96% of couples of
childbearing age who had genetic testing could be reassured
about their status and about the risk of having a child with a
disease that remains severe.3.3. Estimation of the proportion of carriers identified in the
newborn screened population
The results of our NBS programme allowed us to determine
the incidence of CF (q2 =1/2 569) and to deduce the carrier rate
(2pq=1/26) in our population (assuming HW equilibrium).
Based on this carrier rate, we calculated that among the 200
378 newborns screened in our district over the study period, 7
707 should in theory be CF carriers (200 378*1/26), but only
202 were identified by our programme. This indicates that NBS
led to the identification of only 2.6% (202/7 707) of all the
theoretical healthy carriers born within this period (Table 1).
Because our NBS strategy has changed with the implementa-
tion of the NBS programme in the entire country in 2002 (i.e. use
of a commercial kit of 30 mutations instead of scanning of three
exons), we re-estimated this rate for 2002–2010. We observed
that NBS allowed the identification of only 1.9% (54/2879) of the
expected carriers born in our district (Table 1).
3.4. Estimation of the proportion of carriers identified in the
increased IRT level newborn population
With respect to the number of children who had an increased
IRT level in our district over the 1991–2010 period and the CF
Table 1
Estimation of the proportions of carriers identified in the whole screened
population and in the population of newborns with high IRT levels at time of NBS.
Newborn screening programme in Finistère
Newborns screened
1991–2010 Newborn screened (nr) 200 378 Calculated incidence
1 in 2569
Carrier rate 1 in 26
Identified carrier (nr) 202 g 2.6%Expected carrier (nr) 7 707
2002–2010 Newborn screened (nr) 89 268 Calculated incidence
1 in 3719
Carrier rate 1 in 31
Identified carrier (nr) 54 g 1.9%Expected carrier (nr) 2 879
Newborns with increased IRT measure
1991–2010 Increased IRT value (nr) 1 889 Calculated incidence
1 in 24
Carrier rate 1 in 3
Identified carrier (nr) 202 g 33.0%Expected carrier (nr) 612
2002–2010 Increased IRT value (nr) 452 Calculated incidence
1 in 19
Carrier rate 1 in 3
Identified carrier (nr) 54 g 33.8%Expected carrier (nr) 160
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Hardy–Weinberg equilibrium, we were able to show that only
33% (202/612) of the increased IRT children were identified as CF
carriers through NBS (Table 1).
From 2002 to 2010, NBS allowed the identification of only
33.8% (54/160) of the theoretical carriers born over that period
in our district, within the increased IRT group (Table 1).Table 2
Comparison of our results with those reported in the literature.
Reference Area Study period Concerned population E
m
Mischler et al.
Pediatrics [5]
Wisconsin
(USA)
1991–1994 Families with false-
positive IRT/DNA
screening test
Q
1
sw
Ciske et al.
Pediatrics [3]
Wisconsin
(USA)
1994–1997 Families who
responded
Q
Wheeler et al.
Genet Med [7]
Massachusetts
(USA)
1999–2001 Parental couples
of heterozygous
screened children
C
Parsons et al. Arch
Dis Child [6]
Wales
(UK)
1999 Screened carriers
children and parents
In
Lewis et al. J Paediatr
Child Health [4]
Victoria
(AUS)
1996–1997 Families of CF
carriers
Q
2001 Families of CF
carriers
Q
Finistère
(France)
1991–2010 Families of heterozygous
screened children
L
re4. Comments
The present study shows that, in the district of Finistère
(western France) where NBS for CF is based IRT/DNA protocol,
for over 20 years, over 75% of the families of the carrier infants
requested family testing.
Of those 47 families who did not avail of carrier testing, nine
(19.1%) were born more recently (2002–2010) and their
families may still benefit from genetic testing, particularly if
they plan a new pregnancy. Overall, testing has been performed
mostly in close relatives. We identified 183 CF carriers and
detected five new 1-in-4 risk couples, leading to the PD and
termination of one affected pregnancy.
Family testing has proven to be useful in various genetic
disorders whose gene has been identified or in cancers with
genetic component [16–19]. The desirability of cascade testing
in CF-affected families is now well recognised, even if the
frequency of uptake varies between populations [20–23].
A review of the literature shows few articles discussing
cascade testing following the identification of carrier status in
screened newborns (Table 2). The family testing uptake reported
ranges widely according to studies. Indeed, Ciske et al. reported
that only 29.7% of parental couples requested testing, whereas
Parsons et al. reported 100% (10 couples) [3,6]. Within parental
couples, mothers appeared to be more likely to ask for testing
than fathers [3–7]. The use of cascade testing appears to be higher
in our data set. These differences might be explained by the fact
that our study relies on the results of the genetic tests actually
performed in our laboratory, while other studies were based on
interviews [6], questionnaires [3–5] or specific consultations [7]
with the parents of the carrier child. One cannot therefore neglect
the risk of underestimation of testing in those families due to
bias (e.g., recall bias, selection bias). Only, Lewis et al. cross-valuation
ethod
Sample
size
Cascade testing
Parents Relatives
One parent
testing
Both
parents
1-in-4
risk
couple
Family
testing
1-in-4
risk
couple
Father Mother
uestionnaire
year after
eat test
63 0 4.7% 58.0% 0 – –
uestionnaire 138/483 33.8% 41.9% 29.7% – – –
onsultation 95/101 0 14.7% 74.7% 5 – –
terview 10 – – 100% 0 – –
uestionnaire 31 43.0% 63.0% – – 15 –
uestionnaire 35 80.0% 91.0% – 3 – –
aboratory
cords
148/202 – 4.1% 95.9% 3 69 relatives
15 partners
2
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the laboratory, and it appeared that only 91% of the respondents
from the cohort of children born in 2001 were correct in their
recall of their own carrier testing and results (80% in the 1996–97
cohort) [4].
In our population, testing in families of carrier children
identified five new 1-in-4 risk couples. Four of these couples
requested subsequent PD, and one affected pregnancy was
detected and terminated. The number of 1-in-4 risk couples
detected is consistent with the carrier rate observed in our
population (5/156 couples tested=3.2% i.e., 1/31). Those couples
were identified early rather than at the time of NBS result in their
child, allowing them to make informed reproductive choices
(e.g., to request PD or not, to consider that their families are
complete, to embark on pre-implantation genetic diagnosis, to
pursue adoption or to consider egg or sperm donation). However,
the most important point is that almost all of the tested couples
(96.8%) could be assured of their genetic status and about the risk
of having a child with a disease that remains severe and life
limiting, despite important improvements in management over
the past decades.
Our study also highlighted that, assuming Hardy–Weinberg
equilibrium, NBS identified only a very small proportion of the
theoretical carriers that is in keeping with the aims of newborn
screening as stated in the European best practice guidelines on CF
newborn screening [1]. Indeed, NBS led to the identification of
only 2.6% of the carriers expected to be born over the 1991–2010
[24]. This figure dropped to 1.9% since the 3-step IRT-DNA
strategy was implemented nationwide in 2002. Among children
with increased IRT values at the time of NBS, the proportion of
carriers identified was close to 33% in both periods.
Indeed, the purpose of NBS is to identify affected newborns.
To improve its sensitivity and specificity, DNA analysis using
population-specific commercial kit was added to the initial IRT
measurement. The combination of those two techniques led to the
detection of healthyCF carrier newborns with elevated IRT levels.
However, not all carriers had increased IRT levels, and therefore
only a small proportion of carriers were detected via NBS.
The topic of carrier screening has long been debated, and new
approaches are frequently discussed, including the modification
of NBS protocols, e.g., with the introduction of Pancreatitis-
Associated Protein (PAP) measurements. However, even if the
IRT/PAP protocol is considered to perform well, it also appeared
to be less sensitive and less specific than the classical IRT/DNA
assay [25,26].
The issue of how the child and its parents should be
informed of the child's carrier status also arises. The result of the
genetic analysis may generate parental anxiety and may lead them
to stigmatise the screened child [6,27,28]. On the other hand,
information about the healthy carrier status is considered essential
for the families, who express their wish to inform their relatives
[6,29], even if misconceptions and inaccurate information
about the risk associated with being a CF carrier persist [30].
Although in France dissemination of genetic information is
based on the parents, the fact that genetic testing is supported
by the national health system may be considered to be a factor
conducive to the use of test.In conclusion, the carriers detected by NBS, which
represents a small proportion of the theoretical one, appeared
to be well managed in our area. Moreover, cascade testing to
prevent the birth of CF children in those families seems
relatively active. Although this work was performed in only
one district, this study highlights the importance of cascade
testing in families of children identified as carriers through
NBS.
Acknowledgments
The authors thank the Association Française de Dépistage et
de Prévention des Handicaps de l'Enfant (A.F.D.P.H.E.) that
manage the French NBS dataset, and more specifically the
regional team (A.R.D.P.H.E.) in charge of NBS in Brittany.
References
[1] Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A,
Farrell M, et al. European best practice guidelines for cystic fibrosis
neonatal screening. J Cyst Fibros 2009;8(3):153–73.
[2] SuperM, SchwarzMJ,Malone G, Roberts T, Haworth A, DermodyG. Active
cascade testing for carriers of cystic fibrosis gene. BMJ 1994;308(6942):
1462–7.
[3] Ciske DJ, Haavisto A, Laxova A, Rock LZ, Farrell PM. Genetic
counseling and neonatal screening for cystic fibrosis: an assessment of
the communication process. Pediatrics 2001;107(4):699–705.
[4] Lewis S, Curnow L, Ross M, Massie J. Parental attitudes to the
identification of their infants as carriers of cystic fibrosis by newborn
screening. J Paediatr Child Health 2006;42(9):533–7.
[5] Mischler EH, Wilfond BS, Fost N, Laxova A, Reiser C, Sauer CM, et al.
Cystic fibrosis newborn screening: impact on reproductive behavior and
implications for genetic counseling. Pediatrics 1998;102(1 Pt 1):44–52.
[6] Parsons EP, Clarke AJ, Bradley DM. Implications of carrier identification
in newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed
2003;88(6):F467–71.
[7] Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW.
Genetic counseling after implementation of statewide cystic fibrosis
newborn screening: two years' experience in one medical center. Genet
Med 2001;3(6):411–5.
[8] Audrezet MP, Costes B, Ghanem N, Fanen P, Verlingue C, Morin JF,
et al. Screening for cystic fibrosis in dried blood spots of newborns. Mol
Cell Probes 1993;7(6):497–502.
[9] Ferec C, Verlingue C, Parent P, Morin JF, Codet JP, Rault G, et al.
Neonatal screening for cystic fibrosis: result of a pilot study using both
immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Hum
Genet 1995;96(5):542–8.
[10] Scotet V, de Braekeleer M, Roussey M, Rault G, Parent P, Dagorne M,
et al. Neonatal screening for cystic fibrosis in Brittany, France:
assessment of 10 years' experience and impact on prenatal diagnosis. Lancet
2000;356(9232):789–94.
[11] Verlingue C, Mercier B, Lecoq I, Audrezet MP, Laroche D, Travert G, et al.
Retrospective study of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene mutations in Guthrie cards from a large cohort of
neonatal screening for cystic fibrosis. Hum Genet 1994;93(4):429–34.
[12] Scotet V, De Braekeleer M, Audrezet MP, Lode L, Verlingue C, Quere I,
et al. Prevalence of CFTR mutations in hypertrypsinaemia detected through
neonatal screening for cystic fibrosis. Clin Genet 2001;59(1):42–7.
[13] Scotet V, Dugueperoux I, Saliou P, Rault G, Roussey M, Audrezet MP,
et al. Evidence for decline in the incidence of cystic fibrosis: a 35-year
observational study in Brittany, France. Orphanet J Rare Dis 2012;7:14.
[14] Munck A, Roussey M. The French nationwide cystic fibrosis newborn
screening program: strategy and results. Arch Pediatr 2008;15(Suppl. 1):S1–6
[Le depistage neonatal de la mucoviscidose: strategie et resultats nationaux].
344 I. Duguépéroux et al. / Journal of Cystic Fibrosis 12 (2013) 338–344[15] Bilan d'activité AFDPHE. Paris: Association Française pour le Dépistage
et la Prévention des Handicaps de l'Enfant (A.F.D.P.H.E.); 2009 [2011].
[16] Baig SM, Din MA, Hassan H, Azhar A, Baig JM, Aslam M, et al.
Prevention of beta-thalassemia in a large Pakistani family through cascade
testing. Community Genet 2008;11(1):68–70.
[17] Cody N, Green A, McDevitt T, Lynch SA. Cascade screening in
BRCA1/2 mutation carriers. Ir Med J 2008;101(5):140–2.
[18] Helderman-van den Enden AT, van den Bergen JC, Breuning MH,
Verschuuren JJ, Tibben A, Bakker E, et al. Duchenne/Becker muscular
dystrophy in the family: have potential carriers been tested at a molecular
level? Clin Genet 2011;79(3):236–42.
[19] Marks D, Thorogood M, Neil SM, Humphries SE, Neil HA. Cascade
screening for familial hypercholesterolaemia: implications of a pilot study
for national screening programmes. J Med Screen 2006;13(3):156–9.
[20] Lafayette D, Abuelo D, Passero MA, Tantravahi U. Attitudes toward cystic
fibrosis carrier and prenatal testing and utilization of carrier testing among
relatives of individuals with cystic fibrosis. J Genet Couns 1999;8(1):17–36.
[21] McClaren BJ, Metcalfe SA, Aitken M, Massie RJ, Ukoumunne OC, Amor
DJ. Uptake of carrier testing in families after cystic fibrosis diagnosis
through newborn screening. Eur J Hum Genet 2010;18(10):1084–9.
[22] Munck A, Houssin E, Roussey M. The importance of sweat testing for
older siblings of patients with cystic fibrosis identified by newborn
screening. J Pediatr 2009;155(6):928–30 [e1].
[23] Turner G, Meagher W, Willis C, Colley P. Cascade testing for carrier
status in cystic fibrosis in a large family. Med J Aust 1993;159(3):163–5.[24] Dugueperoux I, Audrezet MP, Parent P, Ferec C, Scotet V. Cascade
testing in families of carriers newborns identified through CF newborn
screening in Western Brittany, France. 35th European Cystic Fibrosis
Conference; Dublin, Ireland; 2012 [Journal of Cystic Fibrosis].
[25] Krulisova V, Balascakova M, Skalicka V, Piskackova T, Holubova A,
Paderova J, et al. Prospective and parallel assessments of cystic fibrosis
newborn screening protocols in the Czech Republic: IRT/DNA/IRT
versus IRT/PAP and IRT/PAP/DNA. Eur J Pediatr 2012;171(8):1223–9.
[26] Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, der
Ploeg CP Van, et al. Novel strategies in newborn screening for cystic
fibrosis: a prospective controlled study. Thorax 2012;67(4):289–95.
[27] Beucher J, Leray E, Deneuville E, Roblin M, Pin I, Bremont F, et al.
Psychological effects of false-positive results in cystic fibrosis newborn
screening: a two-year follow-up. J Pediatr 2010;156(5):771–6 [6 e1].
[28] Tluczek A, Koscik RL, Farrell PM, Rock MJ. Psychosocial risk associated
with newborn screening for cystic fibrosis: parents' experience while
awaiting the sweat-test appointment. Pediatrics 2005;115(6):1692–703.
[29] Ormond KE, Mills PL, Lester LA, Ross LF. Effect of family history on
disclosure patterns of cystic fibrosis carrier status. Am J Med Genet C
Semin Med Genet 2003;119C(1):70–7.
[30] Cavanagh L, Compton CJ, Tluczek A, Brown RL, Farrell PM. Long-term
evaluation of genetic counseling following false-positive newborn screen
for cystic fibrosis. J Genet Couns 2010;19(2):199–210.
